Hims & Hers Health (HIMS) Share-based Compensation (2020 - 2026)
Hims & Hers Health (HIMS) reported Share-based Compensation of $39.2 million for Q1 2026, up 52.49% on a YoY basis from $25.7 million in Q1 2025, and down 2.69% sequentially from $40.3 million in Q4 2025.
Hims & Hers Health (HIMS) Share-based Compensation (2020 - 2026) Analysis & Trends
Hims & Hers Health (HIMS) has 7 years of Share-based Compensation data on file, last reported at $39.2 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 52.49% year-over-year to $39.2 million; the trailing twelve-month figure through Mar 2026 stood at $148.7 million (up 151.33% YoY), and the FY2025 full-year result was $135.2 million, up 157.6% from the prior year.
- Share-based Compensation fell to $39.2 million in Q1 2026, from $40.3 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $40.3 million in Q4 2025 to a low of -$30.4 million in Q3 2023.
- A 5-year average of $14.7 million and a median of $19.1 million in 2022 frame the typical range for Share-based Compensation.
- Across the five-year window, Share-based Compensation tumbled 377.08% in 2023 and jumped 973.35% in 2025, its largest moves.
- Tracing HIMS's Share-based Compensation over 5 years: stood at -$29.3 million in 2022, then surged by 119.41% to $5.7 million in 2023, then surged by 241.7% to $19.4 million in 2024, then surged by 107.62% to $40.3 million in 2025, then dropped by 2.69% to $39.2 million in 2026.
- Business Quant data shows HIMS's Share-based Compensation at $39.2 million in Q1 2026, $40.3 million in Q4 2025, and $34.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 43.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 25.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 125.69 Mn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 58.30 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 56.50 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 55.70 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 21.00 Mn |
| 10 | Hims & Hers Health | 6.44 Bn | 5.69 Bn | 396.79 Mn | 39.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 39.21 Mn |
| Mar 31, 2026 | 39.21 Mn |
| Dec 31, 2025 | 40.29 Mn |
| Dec 31, 2025 | 40.29 Mn |
| Sep 30, 2025 | 34.37 Mn |
| Sep 30, 2025 | 34.37 Mn |
| Jun 30, 2025 | 34.87 Mn |
| Jun 30, 2025 | 34.87 Mn |
| Mar 31, 2025 | 25.71 Mn |
| Mar 31, 2025 | 25.71 Mn |
| Dec 31, 2024 | 19.41 Mn |
| Dec 31, 2024 | 19.41 Mn |
| Sep 30, 2024 | 10.82 Mn |
| Sep 30, 2024 | 10.82 Mn |
| Jun 30, 2024 | 3.25 Mn |
| Jun 30, 2024 | 3.25 Mn |
| Mar 31, 2024 | 19.03 Mn |
| Mar 31, 2024 | 19.03 Mn |
| Dec 31, 2023 | 5.68 Mn |
| Dec 31, 2023 | 5.68 Mn |